Physician profile
Christopher Mullin
NPI 1598738023
$2,503.53
in general payments reported to CMS, 2019-2025
27 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $165 · 2021: $209 · 2022: $638 · 2023: $379 · 2024: $643 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $435.44 | 2019-2025 | |
| Astellas Pharma US INC | $249.20 | 2022-2024 | Veozah, Myrbetriq |
| Caldera Medical, INC | $231.89 | 2021-2022 | |
| Sage Therapeutics, LLC | $189.20 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $185.70 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $179.03 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $156.23 | 2021-2022 | |
| Allergan, INC. | $113.57 | 2019-2021 | |
| Pfizer INC. | $99.55 | 2020-2025 | |
| Organon LLC | $97.36 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $69.02 | 2019-2022 | |
| Baxter Healthcare | $67.66 | 2024 | Perclot |
| Exeltis, USA INC. | $57.71 | 2021-2024 | Slynd |
| Daiichi Sankyo INC. | $55.31 | 2023-2024 | Injectafer |
| Ethicon US, LLC | $54.83 | 2023 | Dermabond, Dermabond Prineo, Stratafix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $36.57 | 2023-2024 | Altis |
| Merck Sharp & Dohme LLC | $33.54 | 2019 | |
| Boston Scientific Corporation | $28.23 | 2022 | |
| Hologic Sales and Service, LLC | $27.98 | 2022-2024 | Myosure Tissue Removal Device |
| Millicent US INC | $23.27 | 2025 | Femlyv |
| Medtronic, INC. | $18.44 | 2024 | Venaseal |
| Urovant Sciences INC | $18.27 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.10 | 2022 | |
| Avion Pharmaceuticals | $16.61 | 2022 | |
| Cequr Corporation | $14.93 | 2023 | Cequr Simplicity |
| Olympus America INC. | $14.26 | 2019 | |
| Minerva Surgical, INC | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mullin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.